key: cord-0052051-cbnwutto
authors: Huang, Wen-Chung; Liou, Chian-Jiun; Shen, Szu-Chuan; Hu, Sindy; Hsiao, Chien-Yu; Wu, Shu-Ju
title: Luteolin Attenuates IL-1β-Induced THP-1 Adhesion to ARPE-19 Cells via Suppression of NF-κB and MAPK Pathways
date: 2020-10-16
journal: Mediators Inflamm
DOI: 10.1155/2020/9421340
sha: 62b460347959e48a26237856089ae451b2b1c64a
doc_id: 52051
cord_uid: cbnwutto

Cytokine-induced endothelial dysfunction leads to inflammation and vascular adhesion molecule production in retinal pigment epithelium (RPE) cells. Inflammation is a critical mediator in retinal degeneration (RD) diseases, including age-related macular degeneration (AMD), and RD progression may be prevented through anti-inflammatory activity in RPE cells. The flavonoid polyphenol luteolin (LU) has anti-inflammatory and antidiabetes activities, but its effects regarding retinal protection remain unknown. Here, we examined the ability of luteolin to alleviate markers of inflammation related to RD in cytokine-primed APPE-19 cells. We found that luteolin decreased the levels of interleukin- (IL-) 6, IL-8, soluble intercellular adhesion molecule-1 (sICAM-1), and monocyte chemoattractant protein-1 (MCP-1) and attenuated adherence of the human monocytic leukemia cell line THP-1 to IL-1β-stimulated ARPE-19 cells. Luteolin also increased anti-inflammatory protein heme oxygenase-1 (HO-1) levels. Interestingly, luteolin induced protein kinase B (AKT) phosphorylation, thus inhibiting nuclear factor- (NF-) κB transfer from cytoplasm into the nucleus and suppressing mitogen-activated protein kinase (MAPK) inflammatory pathways. Furthermore, cotreatment with MAPK inhibitors and luteolin decreased inflammatory cytokine and chemokine levels, and further suppressed THP-1 adhesion. Overall, these results provide evidence that luteolin protects ARPE-19 cells from IL-1β-stimulated increases of IL-6, IL-8, sICAM-1, and MCP-1 production by blocking the activation of MAPK and NF-κB signaling pathways, thus ameliorating the inflammatory response.

The retinal pigment epithelium (RPE) is a single layer of pigment cells, which is in close contact with photoreceptors and maintains visual function [1] . RPE exposure to ultraviolet/ visible light leads to oxidative stress and chronic inflammation in the retinal tissue. Inflammation clearly plays a role in the development of age-related macular degeneration (AMD), which is a cause of severe irreversible visual impairment in elderly persons and in diabetic retinopathy [2, 3] . A variety of factors promote retinal tissue degeneration and AMD progression, including genetic and environmental factors, aging, and oxidative stress [4] . AMD involves reduced photoreceptor cells and retinal pigment epithelium dysfunction in the macula and can be classified as "dry AMD" or "wet/exudative/neovascular AMD." Compared to neovascular AMD, dry AMD has a higher incidence, but involves less vision degradation and is thus less frequently a cause of "blindness" [5, 6] . Neovascular AMD is characterized by excessive choroidal neovascularization (CNV) under the retina, leading to retinal edema and even detachment, thereby causing vision loss. Notably, dry AMD can potentially evolve into neovascular AMD, leading to irreversible vision loss [7, 8] . Therefore, the best means of avoiding vision deterioration in elderly persons and cases of diabetic retinopathy is to prevent macular degeneration.

Available data suggest that a number of inflammatory cytokines and chemokines are elevated in the serum or ocular tissue of AMD patients-including interleukin-6 (IL-6), IL-8, monocyte chemotactic protein (MCP-1), and intercellular adhesion molecule (ICAM-1) [9] [10] [11] . Notably, IL-6 levels are increased in the intraocular fluids of patients with neovascular AMD compared to controls, and findings suggest that IL-6 and IL-8 are proangiogenic in AMD progression [12, 13] . Intraocular MCP-1 is a chemokine for monocyte recruitment, and ICAM-1 is an adhesion molecule that facilitates leukocyte transmigration. Studies have reported that elevated MCP-1 levels contribute to subfoveal neovascular membrane development and the degree of macular edema in eyes with exudative AMD and that elevated soluble ICAM-1 (sICAM-1) levels are correlated with choroidal neovascularization [13, 14] . Inflammatory mediators, including chemokines and cytokines, can upregulate ICAM-1 expression. IL-6 could directly or indirectly activate the leukocytes to induce retinal inflammation. It has been found that MCP-1 recruits leukocytes to sites of injury and activates ICAM-1; thus, ICAM-1 induced leukocyte-endothelial interactions and promoted leukocyte migration into extravascular locations involved in the inflammatory response [14, 15] . More studies found that IL-8 and MCP-1 could attract neutrophils and monocytes to migrate into inflammatory tissues. IL-1β is a proinflammatory cytokine and promotes the upregulation of chemokines in RPE as model of focal retinal degeneration [15] . In the present study, we evaluated the ability of the luteolin to modulate inflammation in ARPE-19 cells-THP-1 monocytes interactions. The levels of the inflammatory cytokines IL-6, IL-8, MCP-1, and ICAM-1 in ocular tissue are significantly associated with exudative AMD occurrence and progression [4] . Moreover, IL-1β activates inflammatory-related pathways, including nuclear factor-(NF-) κB and mitogen-activated protein kinase (MAPK) signaling, thus enhancing the production of the proinflammatory mediators MCP-1, IL-6, cyclooxygenase-2 (COX-2), and inducible nitric oxide synthase (iNOS). Proinflammatory mediators are closely associated with the development and progression of retinal degenerative diseases [15, 16] .

Luteolin (Lu) , 3',4',5,7-tetrahydroxyflavone, is a flavonoid polyphenolic compound found in numerous vegetables (e.g., celery, carrots, broccoli, and peppers), fruits (e.g., apple, mango, blueberry, peaches, and prunes), and herbs (e.g., chrysanthemum flowers and Taraxacum mongolicum) [17] [18] [19] [20] . In previous studies, it was demonstrate that luteolin shows anti-inflammatory, anticancer, neuroprotective, and antiviral properties in vitro and in animal models [21] [22] [23] [24] [25] . Thus, luteolin has been investigated for potential use in the treatment of obesity [26] and obesity-related diseases and for antidiabetic [27] [28] [29] and neuroprotective therapies [30, 31] . In ophthalmological research, luteolin protects against oxidative stress-related damage and decreases inflammation in ARPE-19 cells [32, 33] . Luteolin is protective against diabetes-induced progression of retinopathy and reportedly inhibits expressions of the inflammationrelated markers NF-κB and IL-1β, decreases levels of the lipid peroxidation product malondialdehyde (MDA), and increases the antioxidant glutathione (GSH) in diabetesinduced oxidative stress in the retina [34] . These findings indicate the potential to use luteolin for prevention and treatment of retinal inflammatory diseases.

Based on the available data, we speculate that IL-6, IL-8, MCP-1, and sICAM-1 could be target molecules for AMD therapy or prevention. In the present study, we aimed to assess the mechanisms underlying the luteolin-induced anti-inflammatory effects in ARPE-19 cells stimulated by the proinflammatory cytokine IL-1β ( Figure 1 ).

2.1. Materials. Luteolin (≥98% purity by TLC), cell counting kit-8 assays (CCK-8), and DAPI solution were purchased from Sigma-Aldrich (St. Louis, MO, USA). Human recombinant proinflammatory cytokine IL-1β and enzyme-linked immunosorbent assay (ELISA) kits were purchased from R&D Systems (Minneapolis, MN, USA). The inhibitors PD98059, SP600125, SB202190, and Bay 117082 were purchased from Enzo Life Sciences (Farmingdale, NY, USA). Antibodies against β-actin, COX-2, iNOS, HO-1, AKT, and phosphorylated-(phospho-) AKT were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies against JNK, ERK, p38, phospho-JNK, phospho-ERK, and phospho-p38 were purchased from Millipore (Billerica, MA, USA).

Culture. Luteolin was dissolved in dimethyl sulfoxide (DMSO) to prepare a 100 mM stock solution, which was stored at −20°C. The final culture medium had a DMSO concentration of ≤0.1%, as previously described [16] . The ARPE-19 human retinal pigment epithelial cell line was purchased from Bioresource Collection and Research Center (BCRC, Taiwan) and cultured in Dulbecco's modified Eagle's medium (DMEM)/ F-12 medium (Invitrogen-Gibco, Paisley, Scotland) containing 10% heat-inactivated fetal bovine serum (FBS; Invitrogen-Gibco) and penicillin G (100 U/mL), streptomycin (100 μg/mL), and gentamycin (50 ng/mL). Cells were subcultured every 2-3 days at 37°C in a humidified atmosphere of 5% CO 2 . ARPE-19 cells (2 × 10 5 ) were pretreated with or without various luteolin concentrations (1-30 μM) for 1 h, 2 Mediators of Inflammation and then, IL-1β (1 μg/mL) was added. After 24 h, the ARPE-19 cells were lysed for western blot analysis, and the media samples were subjected to ELISA analysis. The THP-1 human monocytic leukemia cell line was obtained from American Type Culture Collection (Manassas, VA, USA). THP-1 cells were cultured in RPMI 1640 medium (Gibco) containing FBS (10%) at 37°C in a humidified atmosphere of 5% CO 2 and subcultured every 3-4 days.

We assessed the inhibitory effect of luteolin on cell viability using CCK-8 kits (Sigma-Aldrich) as described previously [35] . Cells were seeded at 10 5 cells/well into 96-well plates and treated with luteolin at concentrations of 1-100 μM for 24 h. After treatment, the CCK-8 solution was added, and the plates were incubated at 37°C for 2 h. Finally, cell viability was measured at 450 nm using a microplate reader (Multiskan FC; Thermo, Waltham, MA, USA). The CCK-8 assay with each concentration was carried out in triplicate, and cell viability was reported as a percentage relative to the cells without luteolin treatment. 2.6. Western Blot Analysis. Protein samples were separated on 10% SDS polyacrylamide gels and then transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA, USA). Next, the PVDF membranes were incubated overnight at 4°C with specific primary antibodies against β-actin (Sigma), COX-2, iNOS, HO-1, AKT, pAKT (Santa Cruz, CA, USA), JNK, pJNK, p38, and pp38 (Cell Signaling Technology, Danvers, MA, USA). Then, the membranes were washed three times using tris-buffered saline with Tween 20 (TBST) buffer and incubated with secondary antibodies at room temperature for 1 h. Proteins were detected using Luminol/Enhancer solution (Millipore), and signals were detected using the BioSpectrum 600 system (UVP, Upland, CA, USA) to quantitate protein bands. Mediators of Inflammation cells. Finally, the extent of adhesion of THP-1 cells to ARPE19 cells was observed under fluorescence microscope (4 per view; magnification, ×200; Olympus Corporation, Tokyo, Japan). The control groups were treated with IL-1β alone, and all experiments were repeated three times.

2.8. Immunofluorescence Staining. ARPE19 cells were seeded into 6-well plates until reaching 50-60% confluence and pretreated with or without luteolin (1, 3, 10, and 30 μM) for 1 h, followed by addition of IL-1β for 15 min. Then, the medium was suctioned out, and the cells were washed with PBS. The cells were fixed with 4% (w/v) paraformaldehyde and incubated with anti-NF-κB p65 antibody overnight at 4°C. The next day, the medium was removed, and the cells were washed with PBS and then incubated with secondary antibodies at room temperature for 1 h. Then, the cells were washed 2-3 times with PBS, followed by the addition of fluorescent dye (BODIPY493/503 or BODIPY581/591). The cells were again washed with PBS to remove the dye, and 4',6-diamidino-2-phenylindole (DAPI; Sigma) was added to stain the nucleus. Finally, images were acquired using a fluorescence microscope (Olympus, Tokyo, Japan).

2.9. Statistical Analysis. Image Lab software (Bio-Rad) was used to quantify the intensity of western blot bands, and ImageJ software (W. Rasband, NIH, USA) to determine the numbers of THP-1 cells in the adhesion assay. Data were presented as the mean ± standard deviation (SD) from at least three independent experiments. Statistical analyses included one-way analysis of variance (ANOVA) followed by the Tukey's post hoc test. A p value of < 0.05 was considered significant.

and Increased Anti-Inflammatory Protein HO-1 Expression in IL-1β-Stimulated ARPE19 Cells. First, we performed a CCK-8 assay to assess luteolin cytotoxicity in ARPE-19 cells. Luteolin concentrations of ≤50 μM showed no significant cytotoxicity in ARPE-19 cells, while cell numbers were significantly reduced at concentrations of ≥100 μM (Figure 2(a) ). Therefore, all subsequent experiments were performed using 1-30 μM luteolin. ARPE-19 cells were seeded in 6-well plates, treated with luteolin, and then stimulated with 1 ng/mL IL-1β. Compared with IL-1β alone, additional treatment with luteolin at ≥1 μM significantly inhibited expression of the inflammatory mediator iNOS (Figures 2(b) and 2(c)) but did not significantly inhibit COX-2 expression (data not shown). Notably, compared with IL-1β alone, treatment with 1 and 30 μM luteolin significantly increased expression of the anti-inflammatory protein HO-1 (Figures 2(d) and 2(e)). Previous studies have indicated that AKT activation may contribute to inhibiting the NF-κB inflammatory pathway in inflammation-related diseases [36] . Our results showed that luteolin at ≥1 μM enhanced the expression of phosphorylated AKT proteins in IL-1β-stimulated ARPE19 cells compared with in cells treated with IL-1β alone (Figures 2(f) and 2(g)).

Attenuated THP-1 Cell Adherence to IL-1β-Stimulated ARPE-19 Cells. ARPE-19 cells were pretreated with luteolin (1, 3, 10, or 30 μM) for 1 h, and then, 1 ng/mL IL-1β was added for 24 h. IL-1β treatment alone significantly stimulated ARPE19 cells to release cytokines and chemokines compared with control cells. Luteolin at concentrations of 10 and 30 μM significantly inhibited the IL-1β-induced release of IL-6 and IL-8 and decreased the levels of the cell adhesion molecule sICAM-1. Additionally, treatment with 30 μM luteolin significantly decreased MCP-1 levels compared to treatment with IL-1β alone (Figures 3(a)-3(d) ). Since luteolin concentrations of ≥10 μM strongly inhibited sICAM-1 levels, we further investigated whether luteolin attenuated THP-1 cell adhesion to IL-1β-stimulated ARPE-19 cells. Pretreatment with luteolin significantly inhibited THP-1 cell adherence to IL-1β-stimulated ARPE-19 cells, compared to samples treated with IL-1β alone (Figures 3(e) and 3(f)).

Cell Adherence to IL-1β-Stimulated ARPE-19 Cells. We observed that luteolin significantly increased AKT activation (Figures 2(f) and 2(g) ), and pAKT has previously been associated with inhibition of the NF-κB inflammatory pathway [37] . Therefore, we evaluated whether luteolin inhibited NF-κB in relation to the suppression of THP-1 cell adherence to IL-1β-stimulated ARPE-19 cells. Cells were pretreated with or without luteolin (1-30 μM) for 1 h, then stimulation with IL-1β (1 ng/mL) for 15 min, to investigate whether luteolin inhibited NF-κB p65 translocation. Immunofluorescence staining revealed that luteolin at ≥10 μM suppressed NF-κB p65 translocation from the cytoplasm into the nucleus and that the p65 subunit was retained in the cytoplasm in ILβ-activated ARPE-19 cells (Figure 4(a) ). Then, we evaluated whether luteolin inhibited IκB phosphorylation. Treatment with luteolin at ≥1 μM significantly inhibited phosphorylated IκB expression, compared with IL-1β alone (Figure 4(b) ). We further investigated whether luteolin decreased THP-1 cell adherence to ARPE-19 cells via inhibition of NF-κB p65 activation. First, ARPE-19 cells were pretreated with either luteolin (10 μM) or Bay 11-7082 (5 μM) for 1 h and then stimulated with IL-1β. Second, these pretreated ARPE-19 cells were cocultured with labeled THP-1 cells. Our results showed that both luteolin and Bay 11-7082 pretreatment significantly inhibited THP-1 cell adherence to IL-1β-stimulated ARPE-19 cells compared to cells treated with IL-1β alone (Figures 4(b) and 4(c) ). We further evaluated whether the MAPK-inhibiting effects of luteolin were associated with decreased THP-1 adherence to ARPE-19 cells. ARPE-19 cells were pretreated with 10 μM luteolin and/or 10 μM of the JNK inhibitor SP60012, the ERK1/2 inhibitor PD98059, or the p38 inhibitor SB202190 for 1 h, followed by incubation with IL-1β (1 ng/mL) for 24 h. All tested pretreatments decreased THP cell adherence to ARPE-19 cells. Moreover, combined pretreatment with luteolin plus SP60012 or luteolin plus SB202190 resulted in significantly greater reductions of THP-1 adhesion compared to treatment with any of these agents alone ( Figures 5(c) , 5(d), 6(c), 6(d), 7(c), and 7(d)).

Chemokines in IL-1β-Stimulated ARPE-19 Cells. We observed that luteolin significantly decreased the release of IL-6, IL-8, sICAM-1, and MCP-1 in IL-1β-stimulated ARPE-19 cells (Figures 3(a)-3(d) ), as well as significantly suppressed MAPK pathways (Figures 5(a) , 5(b), 6(a), 6(b), 7(a), and 7(b)). Next, we investigated whether MAPK inhibitors could attenuate the IL-1β-stimulated production of the inflammatory cytokines IL-6, IL-8, and MCP-1. ARPE-19 cells were pretreated with luteolin and/or MAPK inhibitors (10 μM SB202190, 10 μM PD98059, or 10 μM SP600125) for 1 h and then incubated with 1 ng/mL IL-1β for 24 h. Interestingly, the pretreatment with MAPK inhibitors and luteolin significantly reduced the levels of IL-6, IL-8, sICAM-1, and MCP-1 in IL-1β-stimulated ARPE-19 cells (Figures 8(a)-8(d) ). These results suggested that in IL-1βstimulated ARPE-19 cells, luteolin suppressed the expression of IL-6, IL-8, sICAM-1, and MCP-1 by influencing the phosphorylation of p38, ERK1/2, and JNK1/2.

In many retinal degenerative (RD) diseases, the pathogenesis is inflammation-induced, involving the recruitment and activation of microglia and macrophages, the expression of inflammatory mediators (COX-2 and iNOS), and photoreceptor cell death. The proinflammatory cytokine IL-1β triggers inflammatory responses and attracts inflammatory cells to migrate into the retina, promoting retinal impairment and degeneration in RD diseases [38, 39] . Numerous studies reported that IL-1β activates the expression of other proinflammatory cytokines and modulates chemokine expression. Proinflammatory cytokines can target and induce retinal inflammation in RD pathogenesis [36, 37] and the phytochemical luteolin has excellent anti-inflammatory properties [32, 33] . Therefore, here we performed a detailed exploration of the anti-inflammatory effects of luteolin in IL-1β-stimulated ARPE19 cells.

Prior studies have indicated that the cytokines IL-6 and IL-8 are proangiogenic, while the chemokine MCP-1 and cell adhesion molecule ICAM-1 facilitate leukocyte transmigration into ocular tissue, in AMD development and progression [4, [12] [13] [14] . Elevated IL-1β levels in the vitreous or retina lead to photoreceptor cell death in retinal detachment patients and in a mouse model, while reduced IL-1β levels inhibit photoreceptor cell death [40] . In the present study, we demonstrated that luteolin significant inhibited cytokine and chemokine release in IL-1β-stimulated ARPE-19 cells (Figures 3(a)-3(d) ). Prior studies have also shown that ICAM-1 is upregulated in response to inflammatory mediators and mediates leukocyte adhesion and transmigration on the RPE, while decreased ICAM-1 levels can suppress Mediators of Inflammation monocyte adhesion in RPE cells [41, 42] . Here, we demonstrated that luteolin inhibited sICAM-1 levels and attenuated THP-1 cell adhesion to IL-1β-stimulated ARPE-19 cells (Figure 3(e) ). We also found that luteolin significantly inhibited iNOS protein expression and increased HO-1 protein expression (Figures 2(b) and 2(d) ). These findings support that luteolin is indeed an anti-inflammatory phytochemical that can attenuate proinflammatory cytokine-induced inflammation in ARPE-19 cells. IL-1β activation of NF-κB signaling is closely associated with RD diseases [15, 16] and pAKT is related to inhibition of the NF-κB inflammatory pathway [36] . Previous studies Mediators of Inflammation show that IL-1β-activates NF-κB, resulting in its translocation from the cytoplasm into the nucleus, followed by induction of cytokine and chemokine expressions in ARPE-19 cells [43] . Our present results showed that luteolin promoted AKT phosphorylation (Figures 2(f) and 2(g) ), inhibited NF-κB p65 activation, and suppressed THP-1 cell adhesion ( Figure 4) . These findings suggest that luteolin promotes AKT phosphorylation to block NF-κB p65 activation and thereby suppresses THP-1 cell adherence to IL-1β-stimulated ARPE-19 cells. Many studies have indicated that MAPK signaling plays an important role in AMD [44] . We observed that luteolin decreased the expression levels of IL-6, IL-8, sICAM-1, and MCP-1 in IL-1β-stimulated ARPE-19 cells. Thus, we further investigated whether luteolin attenuated Mediators of Inflammation inflammation by suppressing MAPK pathways. Our results demonstrated that luteolin significantly inhibited the phosphorylation of the MAPKs JNK 1/2, ERK 1/2, and p38, supporting that luteolin may block MAPK pathways to decrease production of IL-6, IL-8I, sICAM-1, and MCP-1 ( Figures 5(a) , 5(b), 6(a), 6(b), 7(a), and 7(b)).

Human and animal studies have demonstrated that specific MAPK inhibitors may be potential therapeutic targets for RD disease treatment [44] . To explore the importance of individual MAPKs, we used the MAPK inhibitors SP600125 (JNK 1/2 inhibitor), PD98059 (ERK 1/2 inhibitor), and SB202190 (P38), individually and as cotreatments with luteolin in IL-1β-stimulated ARPE-19 cells. We found that luteolin and MAPK inhibitors decreased THP-1 cell adherence to IL-1β-stimulated ARPE-19 cells (Figures 5(c) , 5(d), 6(c), 6(d), 7(c), and 7(d)). We further found that these MAPK inhibitors attenuated the IL-1β-stimulated production of the inflammatory cytokines IL-6, IL-8, sICAM-1, and MCP-1 (Figures 8(a)-8(d) ). These results suggested that luteolin blocked MAPK pathways and inhibited the expression of inflammation-related cytokines-thereby suppressing THP-1 adhesion. 

Our present data demonstrate that luteolin suppressed proinflammatory cytokine-induced retinal pigment epithelium (RPE) inflammation via inactivation of the NF-κB pathway in IL-1β-stimulated ARPE-19 cells. Moreover, cotreatment with MAPK inhibitors plus luteolin attenuated THP-1 cell adhesion to IL-1β-stimulated ARPE-19 cells. Importantly, 

The retinal pigment epithelium in visual function

The impact of oxidative stress and inflammation on RPE degeneration in non-neovascular AMD

Para-inflammation in the aging retina

Inflammatory mechanisms of agerelated macular degeneration

Recent developments in agerelated macular degeneration: a review

Screening for impaired visual acuity in older adults: updated evidence report and systematic review for the US Preventive Services Task Force

Prevalence and causes of blindness and diabetic retinopathy in Southern Saudi Arabia

Choriocapillaris breakdown precedes retinal degeneration in age-related macular degeneration

Relationship between systemic cytokines and complement factor H Y402H polymorphism in patients with dry age-related macular degeneration

Markers of inflammation, oxidative stress, and endothelial dysfunction and the 20-year cumulative incidence of early age-related macular degeneration: the Beaver Dam Eye Study

Progression of age-related macular degeneration: prospective assessment of C-reactive protein, interleukin 6, and other cardiovascular biomarkers

Inflammatory cytokines in aqueous humor of patients with choroidal neovascularization

Cytokine concentration in aqueous humor of eyes with diabetic macular edema

Monocyte chemoattractant protein 1, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1 in exudative agerelated macular degeneration

Editorial: IL-1 family members in health and disease

Schizandrin A protects human retinal pigment epithelial cell line ARPE-19 against HG-induced cell injury by regulation of miR-145

Luteolin, a bioflavonoid inhibits colorectal cancer through modulation of multiple signaling pathways: a review

Flavonoid (myricetin, quercetin, kaempferol, luteolin, and apigenin) content of edible tropical plants

Antioxidant activities of different colored sweet bell peppers (Capsicum annuum L.)

Luteolin: a flavonoid that has multiple cardio-protective effects and its molecular mechanisms

Anti-inflammatory effects of luteolin: a review of in vitro, in vivo, and in silico studies

Luteolin, a flavonoid, as an anticancer agent: a review

Luteolin as an antiinflammatory and neuroprotective agent: a brief review

COVID-19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin

Luteolin decreases the yield of influenza a virus in vitro by interfering with the coat protein I complex expression

Feeding brown fat: dietary phytochemicals targeting non-shivering thermogenesis to control body weight

WSF-7 inhibits obesitymediated PPARγ phosphorylation and improves insulin sensitivity in 3T3-L1 adipocytes

Luteolin reduces adipose tissue macrophage inflammation and insulin resistance in postmenopausal obese mice

Relationship of phenolic composition of selected purple maize (Zea mays L.) genotypes with their anti-inflammatory, antiadipogenic and anti-diabetic potential

The combination of luteolin and l-theanine improved Alzheimer disease-like symptoms by potentiating hippocampal insulin signaling and decreasing neuroinflammation and norepinephrine degradation in amyloid-β-infused rats

Bioavailability and pharmacotherapeutic potential of luteolin in overcoming Alzheimer's disease

Fisetin and luteolin protect human retinal pigment epithelial cells from oxidative stress-induced cell death and regulate inflammation

Two dietary polyphenols, fisetin and luteolin, reduce inflammation but augment DNA damage-induced toxicity in human RPE cells

Effects of luteolin on retinal oxidative stress and inflammation in diabetes

Licochalcone A inhibits cellular motility by suppressing Ecadherin and MAPK signaling in breast cancer

IL-1 family members mediate cell death, inflammation and angiogenesis in retinal degenerative diseases

Regulation of inflammatory response by 3-methyladenine involves the coordinative actions on Akt and glycogen synthase kinase 3β rather than autophagy

Activation of liver X receptor delayed the retinal degeneration of rd1 mice through modulation of the immunological function of glia

Overview of the IL-1 family in innate inflammation and acquired immunity

Macrophageand RIP3-dependent inflammasome activation exacerbates retinal detachment-induced photoreceptor cell death

TNF-α-induced ICAM-1 expression and monocyte adhesion in human RPE cells is mediated in part through autocrine VEGF stimulation

ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-α-activated vascular endothelium under flow

Nepetin inhibits IL-1β induced inflammation via NF-κB and MAPKs signaling pathways in ARPE-19 cells

Targeting MAPK signaling in age-related macular degeneration

This research was supported by grants from the Chang Gung Memorial Hospital (CMRPF1G0203, CMRPF1J0041), Ministry of Science and Technology (MOST 108-2320-B-255-004-), and Chang Gung University of Science and Technology (ZRRPF3J0081) of Taiwan.

Mediators of Inflammation luteolin significantly reduced the expression levels of IL-6, IL-8, sICAM-1, and MCP-1 in IL-1β-stimulated ARPE-19 cells. Taken together, our findings suggest that luteolin blocks MAPK pathways, thus decreasing the expression levels of IL-6, IL-8, sICAM-1, and MCP-1, and thereby suppressing THP-1 cell adhesion to IL-1β-stimulated ARPE-19 cells ( Figure 9 ). We conclude that the natural agent luteolin may ameliorate inflammation-induced retinal degenerationrelated disorders via inhibition of the NF-κB and MAPK pathways in IL-1β-stimulated ARPE19 cells.

Retinal pigment epithelium cells RD:Retinal degeneration AMD:Age-related macular degeneration ARPE-19 cells: Human retinal pigment epithelial cells LU:Luteolin IL-1β:Interleukin-1β IL-6:Interleukin-6 IL-8:Interleukin-8 sICAM-1:Soluble intercellular adhesion molecule-1 MCP-1:Monocyte chemoattractant protein-1 HO-1:Heme oxygenase-1 AKT:Protein kinase B iNOS:Inducible nitric oxide synthase NF-κB:Nuclear factor-κB MAPK:Mitogen-activated protein kinase ELISA:Enzyme-linked immunosorbent assay JNK:c-JUN N-terminal kinase ERK:Extracellular signal-regulated kinase.

The data used to support the findings of this study are available from the corresponding author upon request.

The authors declare that there is no conflict of interests regarding the publication of this paper.

Wen-Chung Huang and Chian-Jiun Liou are equal contributors to the work.